DC57100 · Updated 27 October 2026
Acuitas A9
Instructions for Use
Before use
Check the supplied lot number, batch COA, approved SDS, quantity and retest date. Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
For small quantities of viscous or oily lipid, volumetric transfer can reduce weighing losses. Confirm solvent compatibility and solubility before preparing a stock; calculated volumes do not establish solubility.
Stock-solution planning
Volume (mL) = mass (mg) × 1000 / [molecular weight × concentration (mM)].
| Mass | 10 mM | 20 mM |
|---|---|---|
| 10 mg | 1.1044 mL | 0.5522 mL |
| 25 mg | 2.7609 mL | 1.3804 mL |
| 50 mg | 5.5218 mL | 2.7609 mL |
| 100 mg | 11.0435 mL | 5.5218 mL |
Literature formulation reference
| Component | DC Chemicals product | Molecular weight | Molar ratio | Mass at 1 µmol total lipid (mg) |
|---|---|---|---|---|
| Acuitas A9 / Compound 9 | DC57100 | 905.51 | 50 | Not calculable from disclosed data |
| DSPC | DC57005 | 790.15 | 10 | Not calculable from disclosed data |
| Cholesterol | DCD-041 | 386.65 | 38.5 | Not calculable from disclosed data |
| PEG-DMA (ditetradecylacetamide PEG lipid) | Not uniquely mapped | Not established | 1.5 | Not calculable from disclosed data |
This table follows US10221127B2, Example 29, Table 3. Its amide-based PEG-DMA is not the PEG-DMG used in Table 2. Holland et al. later report ionizable lipid:DSPC:cholesterol:PEG lipid = 54.6:10.9:32.8:1.6 (rounded total 99.9). A specific commercial PEG identity and a single Compound 9 N/P value were not confirmed. Supporting Information Table S2 names mPEG-DMA in the GVS-18-B6 formulation, but that table is not an A9-specific post-formulation composition measurement.
Read the complete study conditions, biological results, tolerability and figures →
References
- Du X, Ansell SM. US10221127B2. Lipids and lipid nanoparticle formulations for delivery of nucleic acids. 5 March 2019. Compound 9; Examples 28–30, Table 3.
- Holland R, Lam K, Jeng S, et al. Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance. ACS Nano 18(15), 10374–10387 (2024). DOI:10.1021/acsnano.3c09028. Table 1, Figures 2–3. Supporting Information Figure S1 and Compound 9 identity entry.
- Buschmann MD et al. Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines 9(1), 65 (2021). DOI:10.3390/vaccines9010065. Review identity context; reference 59.